A Simple Methodology for Conversion of Mouse Monoclonal Antibody to Human-Mouse Chimeric Form
Passive immunotherapy has mainly been used as a therapy against cancer and inflammatory conditions. Recent studies have shown that monoclonal antibody-(mAb-) based passive immunotherapy is a promising approach to combat virus infection. Specific mouse mAbs can be routinely generated in large amounts...
Saved in:
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2013-01-01
|
| Series: | Clinical and Developmental Immunology |
| Online Access: | http://dx.doi.org/10.1155/2013/716961 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832550290691194880 |
|---|---|
| author | Vinh T. Dang Kedar D. Mandakhalikar Oi-Wing Ng Yee-Joo Tan |
| author_facet | Vinh T. Dang Kedar D. Mandakhalikar Oi-Wing Ng Yee-Joo Tan |
| author_sort | Vinh T. Dang |
| collection | DOAJ |
| description | Passive immunotherapy has mainly been used as a therapy against cancer and inflammatory conditions. Recent studies have shown that monoclonal antibody-(mAb-) based passive immunotherapy is a promising approach to combat virus infection. Specific mouse mAbs can be routinely generated in large amounts with the use of hybridoma technology but these cannot be used for therapy in human beings due to their immunogenicity. Therefore, the development of chimeric and humanized mAbs is important for therapeutic purpose. This is facilitated by a variety of molecular techniques like recombinant DNA technology and the better understanding of the structure and function of antibody. The human-mouse chimeric forms allow detailed analysis of the mechanism of inhibition and the potential for therapeutic applications. Here, a step-by-step description of the conversion process will be described. The commercial availability of the reagents required in each step means that this experimentation can be easily set up in research laboratories. |
| format | Article |
| id | doaj-art-87b04c39e8104b0f86f4f264527d74b5 |
| institution | Kabale University |
| issn | 1740-2522 1740-2530 |
| language | English |
| publishDate | 2013-01-01 |
| publisher | Wiley |
| record_format | Article |
| series | Clinical and Developmental Immunology |
| spelling | doaj-art-87b04c39e8104b0f86f4f264527d74b52025-02-03T06:07:09ZengWileyClinical and Developmental Immunology1740-25221740-25302013-01-01201310.1155/2013/716961716961A Simple Methodology for Conversion of Mouse Monoclonal Antibody to Human-Mouse Chimeric FormVinh T. Dang0Kedar D. Mandakhalikar1Oi-Wing Ng2Yee-Joo Tan3Infrastructure, Technology & Translational Division, Institute of Molecular and Cell Biology (IMCB), Agency for Science,Technology and Research, 61 Biopolis Drive, 138673, SingaporeDepartment of Microbiology, Yong Loo Lin School of Medicine, National University Health System (NUHS), National University of Singapore, 117597, SingaporeDepartment of Microbiology, Yong Loo Lin School of Medicine, National University Health System (NUHS), National University of Singapore, 117597, SingaporeInfrastructure, Technology & Translational Division, Institute of Molecular and Cell Biology (IMCB), Agency for Science,Technology and Research, 61 Biopolis Drive, 138673, SingaporePassive immunotherapy has mainly been used as a therapy against cancer and inflammatory conditions. Recent studies have shown that monoclonal antibody-(mAb-) based passive immunotherapy is a promising approach to combat virus infection. Specific mouse mAbs can be routinely generated in large amounts with the use of hybridoma technology but these cannot be used for therapy in human beings due to their immunogenicity. Therefore, the development of chimeric and humanized mAbs is important for therapeutic purpose. This is facilitated by a variety of molecular techniques like recombinant DNA technology and the better understanding of the structure and function of antibody. The human-mouse chimeric forms allow detailed analysis of the mechanism of inhibition and the potential for therapeutic applications. Here, a step-by-step description of the conversion process will be described. The commercial availability of the reagents required in each step means that this experimentation can be easily set up in research laboratories.http://dx.doi.org/10.1155/2013/716961 |
| spellingShingle | Vinh T. Dang Kedar D. Mandakhalikar Oi-Wing Ng Yee-Joo Tan A Simple Methodology for Conversion of Mouse Monoclonal Antibody to Human-Mouse Chimeric Form Clinical and Developmental Immunology |
| title | A Simple Methodology for Conversion of Mouse Monoclonal Antibody to Human-Mouse Chimeric Form |
| title_full | A Simple Methodology for Conversion of Mouse Monoclonal Antibody to Human-Mouse Chimeric Form |
| title_fullStr | A Simple Methodology for Conversion of Mouse Monoclonal Antibody to Human-Mouse Chimeric Form |
| title_full_unstemmed | A Simple Methodology for Conversion of Mouse Monoclonal Antibody to Human-Mouse Chimeric Form |
| title_short | A Simple Methodology for Conversion of Mouse Monoclonal Antibody to Human-Mouse Chimeric Form |
| title_sort | simple methodology for conversion of mouse monoclonal antibody to human mouse chimeric form |
| url | http://dx.doi.org/10.1155/2013/716961 |
| work_keys_str_mv | AT vinhtdang asimplemethodologyforconversionofmousemonoclonalantibodytohumanmousechimericform AT kedardmandakhalikar asimplemethodologyforconversionofmousemonoclonalantibodytohumanmousechimericform AT oiwingng asimplemethodologyforconversionofmousemonoclonalantibodytohumanmousechimericform AT yeejootan asimplemethodologyforconversionofmousemonoclonalantibodytohumanmousechimericform AT vinhtdang simplemethodologyforconversionofmousemonoclonalantibodytohumanmousechimericform AT kedardmandakhalikar simplemethodologyforconversionofmousemonoclonalantibodytohumanmousechimericform AT oiwingng simplemethodologyforconversionofmousemonoclonalantibodytohumanmousechimericform AT yeejootan simplemethodologyforconversionofmousemonoclonalantibodytohumanmousechimericform |